We visited Atanis Biotech on 9 September 2026 and discovered how this innovative Swiss biotech company is developing next-generation diagnostics for food allergy. During the visit, participants learned how Atanis' pioneering blood-based mast cell activation test has the potential to provide a safer and more accurate alternative to current diagnostic approaches, while also exploring the company's facilities and meeting the team behind the technology.

LS² Company Visit to Bio-Technopark Schlieren took place on May 28, 2026. During this visit, we visited DISCO Pharmaceuticals, a biotech start-up developing novel cancer therapies by exploring the “surfaceome” of cancer cells, and Microcaps, a Swiss company using advanced microfluidic technology to produce highly precise microcapsules for applications in cosmetics, nutrition, and pharmaceuticals.